{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:38:08Z","timestamp":1791045488331,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with interstitial lung disease (ILD). We built and validated a model using the national inpatient sample (NIS) database to assess the contributory role of GERD in ILD-related hospitalizations mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective analysis, we extracted ILD-related hospitalizations data between 2007 and 2019 from the NIS database. Univariable logistic regression was used for predictor selection. Data were split into the training and validation cohorts (0.6 and 0.4, respectively). We used decision tree analysis (classification and regression tree, CART) to create a predictive model to explore the role of GERD in ILD-related hospitalizations mortality. Different metrics were used to evaluate our model. A bootstrap-based technique was implemented to balance our training data outcome to improve our model metrics in the validation cohort. We conducted a variance-based sensitivity analysis to evaluate GERD's importance in our model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>The model had a sensitivity of 73.43%, specificity of 66.15%, precision of 0.27, negative predictive value (NPV) of 93.62%, accuracy of 67.2%, Matthews Correlation Coefficient (MCC) of 0.3, F1 score of 0.4, and area under the curve (AUC) for the receiver operating characteristic (ROC) curve of 0.76. GERD did not predict survival in our cohort. GERD contribution to the model was ranked the eleventh among twenty-nine variables included in this analysis (importance of 0.003, normalized importance of 5%). GERD was the best predictor in ILD-related hospitalizations who didn\u2019t receive mechanical ventilation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretations<\/jats:title>\n                <jats:p>GERD is associated with mild ILD-related hospitalization. Our model-performance measures suggest overall an acceptable discrimination. Our model showed that GERD does not have a prognostic value in ILD-related hospitalization, indicating that GERD per se might not have any impact on mortality in hospitalized ILD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02407-4","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:03:55Z","timestamp":1680167035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The prognostic value of gastroesophageal reflux disorder in interstitial lung disease related hospitalizations"],"prefix":"10.1186","volume":"24","author":[{"given":"Shehabaldin","family":"Alqalyoobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertis Brit","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogugua Ndili","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2407_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"2407_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","volume":"22","author":"TM Maher","year":"2021","unstructured":"Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197.","journal-title":"Respir Res"},{"key":"2407_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/rheumatology\/keab615","volume":"61","author":"M Orlandi","year":"2022","unstructured":"Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, et al. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology (Oxford). 2022;61:1600\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2407_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2147\/TCRM.S184291","volume":"15","author":"M Ghisa","year":"2019","unstructured":"Ghisa M, Marinelli C, Savarino V, Savarino E. Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag. 2019;15:1081\u201393.","journal-title":"Ther Clin Risk Manag"},{"key":"2407_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S2213-2600(17)30219-9","volume":"5","author":"KA Johannson","year":"2017","unstructured":"Johannson KA, Strambu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, et al. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? Lancet Respir Med. 2017;5:591\u20138.","journal-title":"Lancet Respir Med"},{"key":"2407_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/ph15081033","volume":"15","author":"B Ruaro","year":"2022","unstructured":"Ruaro B, Pozzan R, Confalonieri P, Tavano S, Hughes M, Matucci Cerinic M, Baratella E, Zanatta E, Lerda S, Geri P, et al. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat? Pharmaceuticals (Basel). 2022;15:89.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2407_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-021-01711-1","volume":"22","author":"F Luppi","year":"2021","unstructured":"Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res. 2021;22:109.","journal-title":"Respir Res"},{"key":"2407_CR8","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","volume":"184","author":"JS Lee","year":"2011","unstructured":"Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"2407_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","volume":"4","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381\u20139.","journal-title":"Lancet Respir Med"},{"key":"2407_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12931-018-0866-0","volume":"19","author":"U Costabel","year":"2018","unstructured":"Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res. 2018;19:167.","journal-title":"Respir Res"},{"key":"2407_CR11","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"2407_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.chest.2021.07.2166","volume":"161","author":"S Alqalyoobi","year":"2022","unstructured":"Alqalyoobi S, Liao SY, Qureshi W, Obi ON. National temporal trends in hospitalization and inpatient mortality in patients with pulmonary sarcoidosis in the United States between 2007 and 2018. Chest. 2022;161:152\u201368.","journal-title":"Chest"},{"key":"2407_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684699","volume":"12","author":"T Shao","year":"2021","unstructured":"Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, Alqalyoobi S, Zeki AA, Leung PS, Shuai Z. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations. Front Immunol. 2021;12: 684699.","journal-title":"Front Immunol"},{"key":"2407_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12931-015-0213-7","volume":"16","author":"LT Kuranishi","year":"2015","unstructured":"Kuranishi LT, Leslie KO, Ferreira RG, Coletta EA, Storrer KM, Soares MR, de Castro Pereira CA. Airway-centered interstitial fibrosis: etiology, clinical findings and prognosis. Respir Res. 2015;16:55.","journal-title":"Respir Res"},{"key":"2407_CR15","unstructured":"HCUP NIS Database Documentation. Healthcare Cost and Utilization Project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/nisdbdocumentation.jsp."},{"key":"2407_CR16","unstructured":"HCUP Quality Control Procedures. Healthcare Cost and Utilization Project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/db\/quality.jsp."},{"key":"2407_CR17","unstructured":"HCUP Tools and Software. Healthcare Cost and Utilization Project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/tools_software.jsp."},{"key":"2407_CR18","unstructured":"Elixhauser Comorbidity Software for ICD-10. Healthcare Cost and Utilization Project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidityicd10\/comorbidity_icd10.jsp."},{"key":"2407_CR19","unstructured":"Elixhauser Comorbidity Software for ICD-9. Healthcare Cost and Utilization Project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp."},{"key":"2407_CR20","volume-title":"Classification and regression trees (Wadsworth statistics\/probability)","author":"LFJ Breiman","year":"1984","unstructured":"Breiman LFJ, Olshen RA, Stone CJ. Classification and regression trees (Wadsworth statistics\/probability). Boca Raton: Chapman & Hall; 1984."},{"key":"2407_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/0272-4332.00040","volume":"22","author":"A Saltelli","year":"2002","unstructured":"Saltelli A. Sensitivity analysis for importance assessment. Risk Anal. 2002;22:579\u201390.","journal-title":"Risk Anal"},{"key":"2407_CR22","unstructured":"Saltelli A, S. Tarantola, F. Campolongo, and M. Ratto.: Sensitivity Analysis in Practice \u2013 A Guide to Assessing Scientific Models. New York: Wiley.; 2004."},{"key":"2407_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.32614\/RJ-2014-008","volume":"6","author":"NMG Lunardon","year":"2014","unstructured":"Lunardon NMG, Torelli N. ROSE: a Package for Binary Imbalanced Learning. R Journal. 2014;6:82\u201392.","journal-title":"R Journal"},{"key":"2407_CR24","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna, Italy: R Foundation for Statistical Computing; 2022."},{"key":"2407_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084217","volume":"9","author":"FJ Valverde-Albacete","year":"2014","unstructured":"Valverde-Albacete FJ, Pelaez-Moreno C. 100% classification accuracy considered harmful: the normalized information transfer factor explains the accuracy paradox. PLoS ONE. 2014;9: e84217.","journal-title":"PLoS ONE"},{"key":"2407_CR26","doi-asserted-by":"crossref","unstructured":"Zhu X DI: Knowledge discovery and data mining: challenges and realities. In; 2007","DOI":"10.4018\/978-1-59904-252-7"},{"key":"2407_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12864-019-6413-7","volume":"21","author":"D Chicco","year":"2020","unstructured":"Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genomics. 2020;21:6.","journal-title":"BMC Genomics"},{"key":"2407_CR28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/CCM.0000000000004470","volume":"48","author":"MJ Martin","year":"2020","unstructured":"Martin MJ, Moua T. Mechanical Ventilation and Predictors of In-Hospital Mortality in Fibrotic Interstitial Lung Disease With Acute Respiratory Failure: A Cohort Analysis Through the Paradigm of Acute Respiratory Distress Syndrome. Crit Care Med. 2020;48:993\u20131000.","journal-title":"Crit Care Med"},{"key":"2407_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/0885066621989244","volume":"37","author":"M Schrader","year":"2022","unstructured":"Schrader M, Sathananthan M, Jeganathan N. Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU With Acute Respiratory Failure-A Reevaluation of the Risk Factors and Outcomes. J Intensive Care Med. 2022;37:342\u201351.","journal-title":"J Intensive Care Med"},{"key":"2407_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(18)30301-1","volume":"6","author":"G Raghu","year":"2018","unstructured":"Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018;6:707\u201314.","journal-title":"Lancet Respir Med"},{"key":"2407_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12931-020-01579-7","volume":"21","author":"AW Wong","year":"2020","unstructured":"Wong AW, Lee TY, Johannson KA, Assayag D, Morisset J, Fell CD, Fisher JH, Shapera S, Gershon AS, Cox G, et al. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respir Res. 2020;21:322.","journal-title":"Respir Res"},{"key":"2407_CR32","doi-asserted-by":"publisher","first-page":"1800376","DOI":"10.1183\/13993003.00376-2018","volume":"51","author":"T Tran","year":"2018","unstructured":"Tran T, Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J. 2018;51:1800376.","journal-title":"Eur Respir J"},{"key":"2407_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12931-020-1283-8","volume":"21","author":"J Walscher","year":"2020","unstructured":"Walscher J, Gross B, Morisset J, Johannson KA, Vasakova M, Bruhwyler J, Kreuter M. Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020;21:12.","journal-title":"Respir Res"},{"key":"2407_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201907-1343LE","volume":"201","author":"S Alqalyoobi","year":"2020","unstructured":"Alqalyoobi S, Adegunsoye A, Linderholm A, Hrusch C, Cutting C, Ma SF, Sperling A, Noth I, Strek ME, Oldham JM. Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020;201:250\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"2407_CR35","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383:958\u201368.","journal-title":"N Engl J Med"},{"key":"2407_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","volume":"10","author":"WS Bowman","year":"2022","unstructured":"Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B, Vo V, Echt GA, Leon W, Shah RJ, et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10:593\u2013602.","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02407-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:06:39Z","timestamp":1680167199000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02407-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2407"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02407-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}